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Abstract 
Background and Purpose -Transplantation of bone mesenchymal stem cells 
(BMSCs) represent a potential therapy for ischemic stroke, we sought to evaluate the long-
term effects of these cells treatment on rat pial microcirculation after middle cerebral artery 
occlusion (MCAO). 
Method - Male rats were subjected to 2-hours MCAO followed by an infusion of 1 
x 10
6
 BMSCs  or phosphate-buffered saline into internal carotid artery. Pial 
microcirculation was observed through a closed cranial window at different reperfusion 
time (7, 14 and 28 days) by fluorescence microscopy. Geometric characteristics of pial 
arteriolar networks, permeability increase, leukocyte adhesion, perfused capillary density 
were analyzed. The expression of the most important proteins in the process of 
angiogenesis was evaluated by western blot analysis. Finally, we performed green 
fluorescent protein (GFP)-BMSCs to transplanted to follow their distribution on infarcted 
area. 
Results - The post-ischemic penumbra induced by MCAO is a site of intense 
microvascular reorganization, characterized by new vessel connections resulting in several 
anastomotic arterioles. The intracarotid administration of bone mesenchymal stem cells up 
to 28 days post middle cerebral artery occlusion induced an accelerated pial vascular 
remodeling. These arcades were likely vessels sprouting from preexistent arterioles 
localized in the penumbra area, able to place on the ischemic core, accompanied by 
increased expression of vascular endothelial growth factor and endothelial nitric oxide 
synthase. GFP-BMSCs showed the distribution and organization in infarcted area up to 28 
days of reperfusion. 
Conclusions - Pial vascular remodeling after MCAO mainly involves arteriolar 
networks; the graft of bone mesenchymal stem cells accelerates this processes through 
angiogenic mechanisms. 
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1. INTRODUCTION 
The blood supply to the brain provides it with oxygen, nutrients and a means to 
excrete metabolic waste. If the blood supply is interrupted in any way, then devastating 
consequence can ensue. The brain has an intense metabolism, and the capacity for 
anaerobic metabolism is minimal; interruption of the oxygen supply for a few minutes can 
cause irreversible damage. 
The vascular system is a supporting system, and disease of vascular origin will 
cause secondary alterations in other neural systems. Vascular disease is often identified by 
its characteristic temporal profile of sudden onset, with rapid appearance of specific 
combinations of neurological symptoms. A stroke (´brain attack`) or cerebrovascular 
accident is characterized by a temporary, or permanent, loss of function of brain tissue 
caused by interruption of the vascular supply. Stroke is the third leading cause of death 
after heart disease and cancer. It is most often due to disease or trauma. Brain infarctions 
account for 75% of strokes, and cerebrovascular accidents such as subarachnoid or 
intracerebral hemorrhages account for a further 15%. Head injury accounts for about 1% of 
deaths and up to one-half of road traffic accident-related deaths. It is, like stroke, a 
common cause of death and disability. Following stroke injury, it is important to identify 
the type of stroke, minimize the stroke size and evaluate what treatment options are 
available to either prevent the problem from reoccurring or to maximise recovery of 
function after the event. 
 
1.1 Physiological control of cerebral blood flow      
Brain cells are dependent on aerobic metabolism for their survival; if deprived of 
oxygen for 20s (anoxia), the brain lapses into unconsciousness as the affected neurons 
cease electrical activity. This can become irreversible if it extends beyond 5 min. It takes 
longer for this process to occur in the brainstem and spinal cord. The brain represents 
approximately 2% of the body weight but uses 20% of the available oxygen and 15% of 
the cardiac output. 
 Blood flow is about 750 mL/min, and this remains constant throughout the day, 
whether we are asleep, awake, lying down or standing up. The average blood flow is 50-55 
mL/100g per minute, then ischaemia (lack of bloodborne oxygen) ensues, and infarction 
(tissue cell death) occurse below 20 mL/100g per minute. Maintaining a constant blood 
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flow depends on a constant blood perfusion pressure and vascular resistance. The cerebral 
perfusion pressure is defined as the mean arterial pressure minus the intracranial pressure, 
rather than cerebral venous pressure. This is because the brain is enclosed within the skull, 
and it is the pressure within this ´closed box´ that is effectively acting on the outside of the 
arteries and thus is the one that opposes arterial pressure. The cerebral perfusion pressure 
does not always remain constant, and as mean arterial pressure is closely regulated within 
narrow ranges, changes must occur in the cerebral vascular resistance to compensate for 
changes in perfusion pressure. This occurs through mechanisms intrinsic to the brain: when 
perfusion pressure decreases, vascular pressure decreases; if perfusion pressure increases, 
so does the resistance. Cerebral blood flow is kept relatively constant by several processes. 
 Metabolic mechanisms involve the action of vasodilating agents such as adenosine, 
K
+
, H
+
 and nitric oxide (NO), which regulate arteriole size. Autoregulation is a major 
homeostatic mechanism whose function is to keep blood flow constant over the pressure 
range 60-150 mmHg. It is closely related to local metabolic processes, and use chemical 
and neurogenic mechanisms to control pressure, the most important being the levels of 
carbon dioxide and oxygen. Hypoxia and hypercarbia cause an increase in cerebral blood 
flow, whereas hypocarbia causes a decrease in blood flow, by constricting or relaxing the 
arteriole smooth muscle. These changes are brought about by alterations in the H
+
 
concentration in the extracellular fluid compartment surrounding the blood vessels. 
 Another source of autoregulation is the level of intraluminal pressure within the 
arterioles. Any increase in pressure produces a direct, myogenic response that is sufficient 
to maintain a steady state of perfusion. These processes are not controlled by the 
sympathetic nervous system, as drugs that effect blood pressure do not, in general, have 
any effect on cerebral blood flow. Too much oxygen can also have deleterious effects on 
brain cells. Increased levels of extracellular oxygen can lead to the formation of free 
radical ions, which can damage brain cells by the process of excitotoxicity. 
 Free radicals also destabilize neurotransmitters by changing the tissue pH, and 
causing them to spontaneously oxide, which can further exacerbate the toxicity. Not all 
areas of the brain are equally active at the same time. Oxygen is shunted around to areas 
(and cells) that need it most for a particular task at a particular time because they are more 
metabolically active. For example, there is relatively more blood flow to the motor cortex 
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when someone is performing a motor task. This suggest that blood is shunted around to 
whichever area needs it. 
 A consequence of this is that areas that are not actively processing information 
have a decreased bood flow. This observation has led to the development of brain scan 
techniques that measure regional cerebral blood flow to functionally active areas following 
injection of radioactive isotope of the inert gas xenon (
133
Xe) into an artery. This was the 
first method used to provide detailed insight into how various brain areas functioned in 
normal and pathological conditions, because of the direct relationship between blood flow 
and cellular metabolic activity [1].         
     
1.1.1 Blood supply to the brain 
Blood is supplied to the brain via the anterior and posterior circulations. The 
anterior circulation supplies supratentorial structures (the cortex and diencephalon), 
whereas the posterior circulation supplies the structures in the posterior fossa (cerebellum 
and brainstem). 
 Both circulations initially arise from the aortic arch, but the posterior circulation 
enters the skull cavity through the foramen magnum, while the anterior circulation enters 
through the foramen lacerum, to lie within the cavernous sinus. 
The anterior circulation carries 80% of the blood supply to the brain. It is derived 
from the internal carotid arteries (ICAs), which branch off from the common carotid 
arteries and enter the brain cavity through the carotid canal (in the petrosal and sphenoid 
bones of the skull) to emerge on its interior surface via the foramen lacerum (which is only 
visible in a dried skull, as in life it is filled with cartilage). The arteries make a series of 
stepwise turns, passing through the cavernous sinus, before emerging, on each side, next to 
the optic chiasm, where they divide into their major branches, the middle cerebral artery 
(MCA) and anterior cerebral artery (ACA). The two anterior cerebral arteries are 
connected by the anterior communicating artery. The posterior circulation comprises the 
vertebral, basilar and posterior cerebral arteries (PCAs), and they convey the remaining 
20% of the arterial supply to the posterior fossa brain structures and inferior surface of the 
posterior aspects of the cortex. The anterior and posterior circulations are connected 
together at the base of the midbrain around the optic chiasm by a network of arteries called 
the circle of Willis. The arteries that form the circle of Willis are a single anterior 
 8 
communicating artery, a pair of ACAs, a pair of ICAs, a pair of posterior communicating 
arteries and a pair of PCAs. There is a substantial amount of anatomical variation between 
individuals in the arrangement of this circle, due to developmental changes. During 
embryonic development, the ICA, supplies the ACA, MCA and PCA, but as the brain 
develops, the PCA develops from the basilar artery, as the posterior communicating artery 
atrophies. However, in approximately 20% of people, the embryonic pattern remains and 
the PCA branches off the anterior circulation. Common variations in the circle of Willis 
include absence of one or both posterior communicating arteries, origination of the PCAs 
from an enlarged posterior communicating artery, or multiple small anterior 
communicating arteries. These anastomoses allow for a certain amount of shunting of 
blood from the anterior to posterior circulation or from one side to the other in the event of 
arterial occlusion, but generally the anastomoses are not effective against total occlusion of 
one the major supply arteries [1].    
      
1.1.2 Main terminal branches of the anterior system 
The ICA gives rise to several small branches at its proximal portion before dividing 
into its two main terminal branches, the MCA and ACA. The hypophysial artery forms a 
plexus around the pituitary stalk. The ophthalamic artery is the most proximal branch of 
the ICA. It supplies the orbit, the eye muscles and the retina, and eventually connects to the 
external carotid (facial and superficial temporal) arteries through anastomoses with arteries 
of the forehead and nose (ethmoidal, nasal, supraorbital and supratrochlear). Occlusion of 
the ophthalamic artery is an important diagnostic sign in transient ischaemic attacks. 
 Another artery that is important in providing anastomoses between different arterial 
systems is the posterior communicating artery, which links the carotid and vertebral 
systems. Clinically, this is one of the most frequent sites for aneurysm formation, at the 
junction where it leaves the ICA. The MCA is the largest and most important branch of the 
ICA, and receives 80% of the carotid blood flow. Its proximal part gives off three deep 
branches. The lateral and medial striate arteries supply the striatum and the internal capsule 
regions of the brain. Occlusion of these deep arteries is the chief cause of classic stroke, 
and the most common location is the putamen and internal capsule. The anterior choroidal 
artery supplies parts of the limbic system, the hippocampus and amygdala, in the medial 
temporal lobe, the posterior part of the internal capsule, the optic radiation and the choroid 
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plexus of the inferior horn of the lateral ventricle, which is important in the formation of 
cerebrospinal fluid (CSF). Occlusion of this artery may cause hemiparesis, 
hemianaesthesia, hemianopsia and loss of short-term memory. 
 The more distal part of the MCA travels laterally through the lateral fissure and 
then separates into superior and inferior branches that supply most of the lateral side of the 
brain (frontal, parietal, temporal and occipital regions). This ramification is known as the 
middle cerebral candelabra (from angiographic studies). The branches are named with 
respect to the cortical region that they supply. The ACA supplies the medial side of the 
frontal and parietal lobes as far back as the parieto-occipital sulcus, and overlaps onto the 
orbital and lateral surfaces of the brain. It winds around the genu of corpus callosum before 
dividing into two main terminal branches. The callosomarginal artery supplies the 
cingulate and frontal gyri and the paracentral lobule. The pericallosal artery supplies the 
corpus callosum. On the lateral surface of the brain, its branches anastomose with terminal 
branches of the MCA. The ACA gives off one proximal branch, the recurrent artery of 
Heubner, which supplies the ventral part of the basal ganglia and the anterior limb of the 
internal capsule. It anastomoses with the lateral striate arteries of the MCA. Occlusion of 
this artery is rare but can cause `clumsy hand` syndrome, with contralateral weakness of 
the arm and face [1].    
    
1.1.3 Differentiated properties of brain capillary endothelial cells account 
for the Blood-Brain Barrier 
Brain microvessels are composed of endothelial cells, pericytes with smooth 
muscle-like properties that reside adjacent to capillaries, and astroglial processes that 
ensheath more than 95% of the abluminal microvessel surface. It was originally thought 
that the glial foot processes formed the blood-brain barrier, but electron-microscopic 
studies identified the endothelial cell as the principal anatomic site of the blood-brain 
barrier. 
 The blood-brain barrier results from specialized properties of the endothelial cells, 
their intercellular junctions, and a relative lack of vesicular transport. In capillaries of 
peripheral organs and in the relatively few brain capillaries that do not form a barrier (eg, 
the circumventricular organs) blood-borne polar molecules diffuse passively across vessels 
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through spaces between endothelial cells, through specialized cytoplasmic fenestrations, or 
by fluid-phase or receptor-mediated endocytosis.  
 Endothelial cells of blood-brain barrier vessels are relatively deficient in vesicular 
transport. They also are not fenestrated. Instead they are interconnected by complex arrays 
of tight junctions. These junctions between the endothelial cells block diffusion across the 
vessel wall. All endothelial cells are interconnected by tight junctional complexes but 
normally have low resistance (5-10 Ω/cm2). In the vessels of the blood-brain barrier, 
however, the resistance is very high (2000 Ω/cm2), and molecules as small as K+ ions are 
excluded. 
 Normal development and brain function require a large number of compounds that 
must be able to cross brain microvessels. Entry into the CSF is achieved primarily in three 
ways: (1) by diffusion of lipid-soluble substances, (2) by facilitative and energy-dependent 
receptor-mediated transport of specific water-soluble substances, and (3) by ion channels. 
The brain is separated from blood only by a very large surface of endothelial cell 
membranes (approximately 180 cm
2
/ g in gray matter). This permits the efficient exchange 
of lipid-soluble gases such as O2 and CO2, an exchange limited only by the surface area of 
the blood vessel and by cerebral blood flow. Barrier vessels are impermeable to poorly 
lipid-soluble molecules such as mannitol, as compared to very lipid-soluble compounds 
such as butanol. The permeability coefficient of the blood-brain barrier for many 
substances is directly proportional to the lipid solubility of the substance as measured by 
the oil-water partition coefficient. 
Most substances that must cross the blood-brain barrier are not lipid soluble and 
therefore cross by specific carrier-mediated transport systems. Because the brain uses 
glucose exclusively as its source of energy, the hexose transporter (glucose transporter 
isotype-1, Glut1) of the blood-brain barrier endothelial cells has been particularly well 
characterized. 
  
 
 
1.2  Stroke  
Stroke is a highly disabling neurodegenerative condition with a high incidence in 
industrialized countries [2].             
Stroke is one of the leading causes of death and the most common cause of adult 
disability. Stroke often causes devastating and irreversible loss of function. There is a wide 
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range of sensory, motor, and cognitive deficits including tremor, lack of coordination, and 
partial paralysis. A stroke occurs when the blood supply to part of the brain is suddenly 
interrupted or when a blood vessel in the brain bursts, spilling blood into the spaces 
surrounding brain cells. The neuronal cell death associated with cerebral ischemia is due to 
the lack of oxygen and glucose, and may involve the loss of ATP, excitotoxicity of 
glutamate, oxidative stress, reduced neurotrophic support, and multiple other metabolic 
stresses. 
 Ischemia ultimately leads to infarction, the death of brain cells which are 
eventually replaced by a fluid-filled cavity (or infarct) in the injured brain. When blood 
flow to the brain is interrupted, some brain cells die immediately, while others remain at 
risk for death. These damaged cells make up the ischemic penumbra and can linger in a 
compromised state for several hours. With timely treatment these cells can be saved. There 
are two forms of stroke: ischemic - blockage of a blood vessel supplying the brain, and 
hemorrhagic - bleeding into or around the brain.  
 
1.2.1 Ischemic Stroke 
An ischemic stroke occurs when an artery supplying the brain with blood becomes 
blocked, suddenly decreasing or stopping blood flow and ultimately causing a brain 
infarction. This type of stroke accounts for approximately 80 percent of all strokes. Blood 
clots are the most common cause of artery blockage and brain infarction. The process of 
clotting is necessary and beneficial throughout the body because it stops bleeding and 
allows repair of damaged areas of arteries or veins. However, when blood clots develop in 
the wrong place within an artery they can cause devastating injury by interfering with the 
normal flow of blood. Problems with clotting become more frequent as people age. Blood 
clots can cause ischemia and infarction in two ways. A clot that forms in a part of the body 
other than the brain can travel through blood vessels and become wedged in a brain artery. 
 This free-roaming clot is called an embolus and often forms in the heart. A stroke 
caused by an embolus is called an embolic stroke. The second kind of ischemic stroke, 
called a thrombotic stroke, is caused by thrombosis, the formation of a blood clot in one of 
the cerebral arteries that stays attached to the artery wall until it grows large enough to 
block blood flow. Ischemic strokes can also be caused by stenosis, or a narrowing of the 
artery due to the buildup of plaque (a mixture of fatty substances, including cholesterol 
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and other lipids) and blood clots along the artery wall. Stenosis can occur in large arteries 
and small arteries and is therefore called large vessel disease or small vessel disease, 
respectively. Brain injury following cerebral ischemia involves a complex succession of 
events that evolve spatially and temporally, causing varying degrees of cell damage 
depending on the characteristics of the initial insult [3]. The ischemic core and the peri-
infarct zone (penumbra) suffer differing degrees of cellular damage [4], and it is widely 
accepted that cell death in the ischemic core is triggered by necrosis while that which 
occurs in the penumbra is predominantly mediated by apoptosis [5]. As apoptosis is a 
reversible process, therapeutic interventions targeting this process have the potential to 
prevent or limit cell death in the peri-infarct zone, even when applied post-ischemia. 
 
1.2.2 Mechanisms of cell injury in ischemic stroke 
The brain has a very high rate of oxidative metabolism. Anaerobic metabolism in 
the brain is negligible, and as a consequence the brain is extremely vulnerable to hypoxic 
damage. Cell death occurs in stroke because of anoxia and the resultant loss of ability of 
the cell to maintain the integrity of the cell membrane through the activity of the energy-
dependent ATPase pumps. The pathophysiological consequences of stroke involve a 
complex sequence of events that involve over time and space and set up several vicious 
circles that ultimately lead to brain cell death. The main mechanisms involved include 
excitotoxicity, inflammation and programmed cell death, and molecular pathways for these 
have been extensively studied. The mechanisms involved are different in different areas of 
the stroke region: at the site of infarct, the core region, hypoxia is most severe and brain 
tissue rapidly dies. Surrounding the core is an area called the ischaemic penumbra, where 
there is residual blood flow and where brain cells undergo potentially reversible 
electrophysiological and metabolic failure. These cells have not yet entered signal cascades 
that lead to cell death. The size of the penumbra is variable. The importance of this 
penumbra is that here the cell damage may be reversible, and those drug treatment that 
block the release and action of excitotoxins may reduce or limit the amount of functional 
deficit. When the brain becomes hypoxic, ATP levels start to fall and the ATP-dependent 
Na
+
 pumps in the neuronal and glial cell membranes become dysfunctional. The Na
+ 
that 
enters the cells, either during action potentials or because of the ongoing leaks in the 
membrane, cannot be pumped out, causing membrane depolarization. This creates an 
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inward osmotic force, as the influx of Na
+
 (and Cl
-
) is much greater than the efflux of K
+
, 
and the cells swell due to the passive influx of water, causing oedema. Cells eventually 
burst as the cell membrane fails; this is necrotic cell death. 
 The brain is encased in a rigid box, the skull, so if the neurons start to swell, this 
will increase the intracranial pressure, leading to compression of the ventricles and the 
cerebral blood vessels. Compression of the blood vessels, expecially the veins, reduces the 
blood flow and hence further decreases the oxygen supply. A vicious circle is set up that 
leads to a rapid decline in cerebral perfusion. Brain oedema is one of the earliest events in 
stroke, and its magnitude is one of the major factors that determine whether the patient will 
survive beyond the first few hours. The reuptake process that removes glutamate from the 
synaptic cleft and stabilizes glutamatergic transmission is also energy-intensive, and thus 
requires ATP. As soon as oxygen levels fall and ATP levels decline, the reuptake process 
slows down. Consequently, glutamate begins to accumulate in the synaptic cleft and, with 
the associated rise in extracellular K
+
, further depolarization of cells may occur. This leads 
to more hyperexcitability and more glutamate release, and yet another vicious circle. 
 Activation of the N-methyl-D-aspartate (NMDA) glutamate receptor leads to Ca
2+
 
influx into neurons. This receptor is normally tightly regulated by a number of factors, so 
that Ca
2+
 entry into neurons is closely controlled. Excessive extracellular glutamate levels 
lead to prolonged neuronal depolarisation via 4-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptors, which in itself is not harmful. However, the 
depolarisation of the postsynaptic cell also activates the NMDA receptor (which is held 
inactive at normal resting potentials by a Mg
2+
 block of the receptor), which in turn leads 
to further Ca
2+
 entry. This is where critical processes are triggered, due to Ca
2+
 overload as 
the Ca
2+
 buffering systems of neurons, the mitochondria and endoplasmic reticulum, fail. 
 The rise in internal Ca
2+
 level activates many second messenger systems, which all 
demand energy in the form of ATP or other substrates. 
 However, because of hypoxia, this energy is not available. Disruption of neuronal 
Ca
2+
 -induced processes leads to the formation of free radicals, such as the superoxide 
anion (O
2-
), via the activation of NO production. These free radicals are very reactive and 
initiate cell damage by reacting with many cell components (e.g. lipid peroxidation 
reaction). This eventually damages the cell so badly that it undergoes necrosis. Thus, 
glutamate toxicity is a prominent cause of necrotic cell death [1].             
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1.2.3 Animal Model of Stroke 
Development of effective stroke therapy requires use of animal models that can 
simulate human pathology in a reproducible and physiologically relevant manner. 
 Currently, the intraluminal suture model of MCAO has been widely used to induce 
ischemic brain lesions. As the MCA is occluded via a cervical carotid approach, this 
obviates the requirement for a craniectomy and the associated problems with opening the 
skull. However, the lesions caused by the MCAO tend to be variable in size; in addition, 
animals have been excluded from analysis by arbitrary criteria such as unexpected 
behavior in most series. The development of reliable and reproducible animal models for 
cerebral ischemia is needed for the systematic study of the pathophysiology and treatment 
of stroke. 
 
 
1.2.4 Stroke treatment and neuroprotection 
The majority of neuroprotective treatments for cerebral ischemia have been 
efficacious in experimental studies but have failed their clinical trials.  
Only i.v. thrombolysis (rtPA) has been shown to be effective; however its narrow 
therapeutic time window makes it a treatment for a reduced percentage of patients [6]. In 
the past, protective therapies have been directed towards saving neural cells. Stroke 
induced damage compromises the integrity of the neurovascular unit [7] through various 
pathophysiologic mechanisms. Angiogenesis, neurogenesis and synaptogenesis are 
interrelated mechanisms that promote brain plasticity and help to repair the neurovascular 
unit and recover neurological function [8]. Endogenous brain plasticity can be stimulated 
by rehabilitation, stimulation and/or administration of trophic factors and cell therapy. The 
different cell lines used in experimental stroke models include embryonic, hematopoietic 
and mesenchymal stem cells (MSCs) [9]. The advantages of MSCs include their 
multipotency, which facilitates in vitro and in vivo tissue repair [10], and their ease of 
isolation, which allows immediate availability for clinical application. 
 
1.3 MSCs 
The transplantation of stem cells may repair injured nervous tissue through 
replacement of damaged cells, hence providing an effective treatment for brain diseases.  
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Stem cells are well known for the self-renewing capacity and multipotential nature 
like high differentiation and “homing” capability, which provides the solid foundation of 
treatment for various diseases. Different populations of adult stem cells that can contribute 
to the regeneration of muscle, liver, heart and vasculature have been described, although 
the mechanisms by which this is accomplished are still not completely understood, (Fig. 1) 
[11]. Several types of stem cells have been transplanted into the injured brain, including 
mesenchymal stem cells (MSCs) [12–13]. Multipotent mesenchymal stem cells (MSCs) 
are in the centre of a rapidly moving field in rheumatology, initially based on their 
cartilage/bone differentiation potential now partly eclipsed by their capacity to counteract 
adverse host immune responses, improve angiogenesis and prevent fibrosis. MSCs are 
characterized by their capacity to adhere to plastic, their phenotype are CD90
+
, CD73
+
, 
CD105
+
, absence of haematopoietic markers including CD45
-
, CD11b
-
, CD14
- 
 and HLA-
DR
-
. MSCs have been found to produce improvements in disease models, although a 
limited number of the cells could be demonstrated to be stably engrafted. The injected 
mesenchymal stem cells home to the injured area, in particular to hypoxic, apoptotic or 
inflamed areas, and release trophic factors that hasten endogenous repair [11]. The basic 
theory of stem cell therapy is that stem cells would replace injured cells, which seems to be 
a part of theories in the treatment for brain diseases. 
 However, other mechanisms are proposed, including the possibility that stem cells 
may release or stimulate release of trophic factors which would be neuroprotective, 
enhance angiogenesis, inhibit fibrosis and apoptosis, and stimulate recruitment, retention, 
proliferation and differentiation of tissue-residing stem cells [11]. 
Their efficacy may rely on the collaboration of secretion of cytokines and direct 
differentiation. It has been demonstrated that MSCs can promote functional recovery by 
producing trophic factors that induce survival and regeneration of host neurons [14]. 
 Besides the neurotrophic factors, MSCs can produce the extracellular matrix 
molecules that can support neural cell attachment, growth and axonal extension [15]. 
Several studies have proved that MSCs can be induced to express neural markers in vitro 
[16, 17], while after stem cells migrating in the brain, some new neurons in the adult 
human hippocampus have been found [14, 18, 19]. There is no precise definition of 
mechanisms of stem cell‐based therapy for brain diseases yet; however, as beneficial 
effects have been demonstrated, details inside cell therapy need further investigation. In 
 16 
addition to the advanced research into the precise mechanisms, strategies should also be 
established to enhance the homing capability of MSCs towards brain lesions for better 
therapeutic effects as well as reducing side effect.  
Over the past 20 years, stem cell technologies have become an increasingly 
attractive option to investigate and treat brain diseases. 
 
 
Figure 1: this figure shows the ability of mesenchymal stem cells (MSCs) in the bone-marrow 
cavity to self-renew (curved arrow) and to differentiate (straight, solid arrows) towards the 
mesodermal lineage. The reported ability to transdifferentiate into cells of other lineages (ectoderm 
and endoderm) is shown by dashed arrows, as transdifferentiation is controversial in vivo. 
 
 
1.3.1 BMSCs for the treatment of ischemic stroke 
There is an urgent need to remodel the injured brain to improve neurological 
outcome after ischemic stroke. Stem cell-based therapy may provide a method to achive 
this (20, 21). 
 Bone mesenchymal stem cells (BMSCs) can be easly obtained from patients 
themselves without ethical or immunological problems and can proliferate massively in 
vitro (Fig. 2). 
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 Under certain conditions, BMSCs can be induced to differentiate into multiple cell 
types, including neurons (22, 23) and endothelial cells (24). Ischemic stroke causes a 
disturbance of neuronal circuitry and disruption of the blood–brain barrier that can lead to 
functional disabilities, which is the most important vascular central nervous system 
disorder that remains a leading cause of death and disability [25]. BMSCs have great 
potential as therapeutic agents in stroke management, since they are easily obtained from 
bone marrow and can be expanded rapidly ex vivo for autologous transplantation [26]. 
Increasing evidences suggest that BMSCs can be used to treat stroke with satisfactory 
results, as BMSCs can migrate to the ischemic areas, secrete some trophic factors. After 
middle cerebral artery occlusion (MCAO), BMSCs that are administered by different 
routes and applied for different time of treatment all show promising therapeutic effects.  
The three major routes of BMSCs administration are intrastriatal, intracarotid, and 
intravenous injection. BMSCs intend to migrate to the region of the ischemic hemisphere 
than to the contralateral non-ischemic hemisphere, and make contribution to the functional 
recovery [27, 28]. Transplanting BMSCs after MCAO has been found significantly 
improving neurological functional recovery, as well as promoting endogenous 
neurogenesis and reducing apoptosis. However, gene modification is always a promising 
way to enhance therapeutic benefits. Rats with ischemic stroke due to MCAO that received 
fibroblast growth factor-2 (FGF-2)-modified BMSCs or BDNF-modified BMSCs had a 
significantly reduced infarction volume 14 days after MCAO [29, 30]. 
 Other combination methods have also been studied and showed great therapeutic 
benefits, which demonstrates that BMSCs have great potential in stroke treatment. 
Transplanting a composite graft of fresh bone marrow along with brain-derived 
neurotrophic factor (BDNF) into the ischemic boundary zone (IBZ) of rat brain can 
facilitate BM cells to survive and differentiate, and improves functional recovery after 
middle cerebral artery occlusion (MCAO) [31].  
Transplanting BMSCs increased expression of brain-derived neurotrophic factor 
(BDNF) [32], nerve growth factor (NGF) [27,32], vascular endothelial growth factor 
(VEGF) [33], basic fibroblast growth factor (bFGF) and so on. These trophic factors 
function in the processes of induction of angiogenesis, neurogenesis and neuroprotection, 
and it seems that these factors/cytokines secreted by BMSCs play most important role in 
functional recovery after MCAO. 
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Figure 2: culture of bone mesenchymal stem cells 
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2. AIM 
Cerebral stroke has been studied in several experimental models, where particular 
attention has been devoted to neuronal dysfunctions, metabolic events and vascular 
involvement [34, 35, 36]. Most of studies, however, have been focused on neuronal 
damage, while no angiogenesis has been documented in areas near the ischemic core, such 
as the necrotic area induced by middle cerebral artery occlusion (MCAO) [37]. Bone 
marrow mesenchymal stem cells (BMSCs), a heterogeneous population of plastic-adherent 
cells, have been used for the treatment of experimental stroke [38]. After ischemia 
breakdown of the blood-brain barrier (BBB) is well known; in normal rat brain 
parenchyma, the integrity of the BBB, it has been demonstrated, using Evans blue 
extravasation, while intense blue was observed in the infarcted lesion at 7, 14 and 28 days 
after MCAO [39]. On the other hand, BMSCs migrate selectively into damaged brain areas 
after intravenously injection at an early phase after ischemia [40, 41]. Specific molecular 
signals, such as stromal cell-derived factor-1 (SDF-1/CXCR4) intracellular signalling, 
adhesion molecules and proteases were involved in the interaction of BMSCs to reach, 
recognize, and function in cerebral ischemic tissue [40]. BMSCs have an inhibitory effect 
on T-cell proliferation triggered by cellular or humoral stimuli [42], while under specific 
conditions, BMSCs can be induced to differentiate in vitro into multiple cell types, 
including neurons [43, 44] and endothelial cells [45]. The ability to form capillaries in 
semisolid medium was tested with an in vitro angiogenesis kit; the cells were cultivated in 
the absence or in the presence of two different concentrations of VEGF. Furthermore, 
when cultured in presence of endothelial growth supplements, the cells start to express 
endothelial markers [46].  Kinnaird et al. have shown that mesenchymal stem cells express 
a wide spectrum of angiogenic growth factors and may stimulate collateral vessel 
formation by paracrine mechanisms after the injection of these cells into the adductor 
muscles of the ischemic hindlimb. They found that local production of bFGF and VEGF 
increased in BMSC-injected tissue and documented colocalization of BMSCs and VEGF 
[47].    
One of the most important questions for a follow-up cell therapy study is the 
ultimate fate of the cells to evaluate whether in vivo these cells are capable to accelerate the 
physiological mechanism of remodeling. Therefore, we observed the pial networks at 
various time points after induction of MCAO to study BMSCs potential therapeutic 
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benefits to generate blood vessels, evaluating geometric characteristics of pial arterioles as 
well as microvascular permeability, leukocyte adhesion to venular walls and capillary 
perfusion. We correlated these vascular observations with the determination of VEGF, 
eNOS, nNOS and iNOS expression to clarify their role during pial arteriolar network 
reorganization [48]. 
Moreover, in this study, we performed in vivo green fluorescent protein (GFP)-
BMSCs to transplanted to follow their distribution on infarcted area. 
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3. MATERIALS AND METHODS 
All experiments were conducted according to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996) and to institutional rules for the care and handling of 
experimental animals. The protocol was approved by the “Federico II” University of 
Naples Ethical Committee. 
 
3.1 Isolation and identification of BMSCs and GFP-BMSCs 
The BMSCs and GFP-BMSCs were isolated under sterile conditions from 8–10 
week-old male Wistar rats and transgenic rats expressing the enhanced green fluorescent 
protein (GFP), respectively, as described previously [49, 50]. Rats were killed by cervical 
dislocation, and marrow was aspirated from femurs and tibiae for cultivation in DMEM 
(Dulbecco’s Modified Eagle’s Medium) supplemented with 10% FBS (fetal bovine 
serum), 100 U/mL penicillin G. About 13 x 10
6
 whole marrow cells were placed in 150-
cm
2
 tissue culture flasks that were coated with collagen I (Sigma Aldrich). After 5 days, 
the non-adherent hematopoietic cells were removed by changing the medium. The culture 
medium was replaced two to three times a week (figure 1). As the culture approached 
confluence, the cells were detached with 0.05% Trypsin and subcultured. Previous studies 
showed that the cultured BMSC highly express CD90, CD44, CD105 and CD166, but not 
CD34 and CD45 [51, 52]. 
 The cells harvested at 3-5 passages were used as BMSCs grafts.  
 
3.2 Experimental groups 
Rats were randomly divided into: a) sham-operated animals (S group, n=9) that 
received the same procedures as the other experimental groups without MCAO; b) 
ischemic group, submitted to 2 hours MCAO and receiving 300 μl cell-free phosphated 
buffer saline (PBS) solution, the animals were observed after 1 hour (C1hR group, n=9), 7 
days (C7R group, n=9), 14 days (C14R group, n=9) and 28 days (C28R group, n=9) of 
reperfusion. c) BMSCs-treated group subjected to 2 hours MCAO and the infusion of 
BMSCs (300 μl PBS solution containing 1 x 106 cells) and observed at: 7 days (BMSCs7R 
group, n=9), 14 days (BMSCs14R group, n=9) and 28 days (BMSCs28R group, n=9) of 
reperfusion. d) GFP-BMSCs-treated group was subjected to 2 hours MCAO and the 
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infusion of 1 x 10
6 
GFP-BMSCs; as controls, the rats were studied after 7 (GFP-7R, n=5), 
14 (GFP-14R, n=5) and 28 days (GFP-28R, n=5) of reperfusion. 
 
3.3 Animal Model 
Adult male Wistar rats (Charles River) weighing 250-300 g were used. MCAO was 
induced by intraluminal filament technique as previously described [53]. In brief, rats were 
anesthetized with intraperitoneal alpha-chloralose (60 mg/kg b.w.), the left common 
carotid artery (CCA), external carotid artery (ECA) and internal carotid artery (ICA) were 
exposed. 
 Subsequently, the ECA was cut with microscissors and heparinised 4-0 nylon 
filament was inserted into stump of ECA and advanced into ICA about 20 mm until it 
blocked the origin of the left middle cerebral artery. To determine the perfusion decrease 
during MCAO, microvascular blood flow was measured by laser Doppler perfusion 
monitoring (LDPM) on the skull of all animals by a Perimed PF5001 was flowmeter, using 
a probe (407; Perimed, Sweden) attached to the bone. The sampling rate was 32 Hz and 
blood flow was expressed as Perfusion Units (PU). After 2 hours occlusion, the filament 
was withdrawn and 1 x 10
6 
BMSCs or GFP-BMSCs in treated groups or cell-free PBS in 
control group was infused by insertion of a catheter, immediately the incision was sutured.  
Successively, the rats were allowed to recover from surgical intervention with free 
access to pellets and water. After 1 hour, 7, 14 and 28 days of reperfusion the animals were 
re-anesthetized, intubated and mechanically ventilated with room air and supplemental 
oxygen. A catheter was placed in the left femoral artery for arterial blood pressure 
recording and blood gases sampling, another one was placed in the right femoral vein for 
injection of the fluorescent tracers [fluorescein isothiocyanate bound to dextran, molecular 
weight 70 KDa (FD 70), 50 mg/100g b.w. i.v. as 5% wt./vol solution in 5 min, and 
rhodamine 6G to label leukocytes 1 mg/100g b.w. in 0.3 mL] and for additional 
anaesthesia. Blood gas measurements were carried out on arterial blood samples 
withdrawn from arterial catheter at 30 min time period intervals (ABL5; Radiometer, 
Copenhagen, Denmark). Mean arterial blood pressure (MABP), heart rate, respiratory CO2 
and blood gases values were recorded and maintained stable within physiological ranges. 
Rectal temperature was monitored and preserved at 37.0  0.5°C with a heating pad, where 
the rats were secured.  
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To observe pial microcirculation, a closed cranial window (4 x 5 mm) was 
implanted above the left parietal cortex (posterior 1.5 mm to bregma; lateral, 3 mm to the 
midline) [54]. The dura mater was gently removed and a 150 m-thick quarz microscope 
coverglass was sealed to the bone with dental cement. The window inflow and outflow 
were assured by two needles secured in the dental cement of the window so that the brain 
parenchyma was continuously superfused with artificial cerebrospinal fluid (aCSF). The 
rate of superfusion was 0.5 mL/min controlled by a peristaltic pump. During superfusion 
the intracranial pressure was maintained at 5 ± 1 mmHg and measured by a Pressure 
Transducer connected to a computer. The composition of the aCSF was: 119.0 mM NaCl, 
2.5 mM KCl, 1.3 mM MgSO4·7H2O, 1.0 mM NaH2PO4, 26.2 mM NaHCO3, 2.5 mM 
CaCl2 and 11.0 mM glucose (equilibrated with 10 % O2, 6 % CO2 and 84 % N2; pH 7.38  
0.02). The temperature was maintained at 37.0  0.5°C [55].  
 
3.4 Fluorescence microscopy and microvascular parameter assessment  
Pial microcirculation was visualized with a fluorescence microscope, as previously 
reported [57]. The arteriolar network was mapped by stop-frame images and pial arterioles 
were classified according to a Strahler method, modified according to diameter [56]. The 
arterioles were classified from the smallest ones, assigned order 1, that gave origin to 
capillaries (order 0), up to the largest arterioles in the preparations, assigned order 5. When 
two vessels of the same order joined, the parent vessel was assigned the next higher orders. 
 If two daughter vessels were of different orders, the parent vessel retained the 
higher of the two orders. The procedure of the pial arteriole classification was previously 
described [57]. 
 Moreover, a “connectivity matrix” was calculated to clarify the number and order 
of daughter arterioles spreading from parent vessels. Briefly, order n vessels may spring 
from orders n + 1, n + 2, …. vessels, the component of which in row n and column m was 
the ratio of the total number of elements of order n sprung from elements in order m [57].  
The increase in permeability was calculated as normalized grey levels (NGL): NGL 
= (I – Ir)/Ir, where Ir is the average baseline grey level at the end of vessel filling with 
fluorescence (average of 5 windows located outside the blood vessels with the same 
windows being used throughout the experimental procedure), and I is the same parameter 
at the end of reperfusion. Grey levels ranging from 0 to 255 were determined by the MIP 
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Image program in five regions of interest (ROI) measuring 50 m2 (10x objective). The 
same location of ROI during recordings along the microvascular networks was provided by 
a computer-assisted device for XY movement of the microscope table.  
Adherent leukocytes (i.e., cells on vessel walls that did not move over a 30-second 
observation period) were quantified in terms of number/100 m of venular length (v.l.)/30s 
using higher magnification (32x, microscope objective). In each experimental group forty 
five venules were studied. The perfused capillary density (PCD) was measured by 
computerized method (MIP Image, CNR, Pisa) in an area of 150 m2 and expressed as 
cm/cm
2
 = cm
-1
. 
     The single pial venule (SPV) blood flow, Q, was calculated according to the 
following equation: Q =  x VCL x A, where  was a constant, related to the vessel 
diameter, VCL was the red blood cell centerline velocity and A was the cross-sectional area. 
SPV blood flow (SBF) was calculated in venules with diameter of 30-40 µm in both left 
and right hemisphere. In rats subjected to MCAO and reperfusion, SBF in affected 
hemisphere was compared with that in contralateral hemisphere. Previous data indicate that 
single pial venule blood flow may be an accurate measure of pial blood flow drainage from 
cerebral cortex, because it represent about 30-60% of cortical blood flow. Therefore, we 
chose to measure single pial venule blood flow to compare with laser Doppler perfusion 
monitoring data and to estimate the difference in perfusion between affected and non 
affected hemisphere. 
MABP (Viggo-Spectramed P10E2 trasducer – Oxnard, CA – connected to a 
catheter in the femoral artery) and heart rate were monitored with a Gould Windograf 
recorder (model 13-6615-10S, Gould, OH, USA). Data were recorded and stored in a 
computer. Blood gas measurements (arterial partial pressure of O2 and CO2 and pH) were 
carried out on arterial blood samples withdrawn from arterial catheter at 30 min intervals 
(ABL5; Radiometer, Copenhagen, Denmark).  
 
3.5 Western blotting analysis  
Proteins were extracted from cortex and striatum tissues, and its concentration was 
determined using the Bio-Rad protein assay kit. Equal amounts of proteins were separated 
by SDS-PAGE under reducing conditions, and then transferred to polyvinylidene 
difluoride membranes (PVDF, Invitrogen). The immunoblot was blocked, incubated with 
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specific antibodies at 4°C overnight, washed and then incubated with a 1:2,000 dilution of 
HRP (horseradish peroxidase)-conjugated IgG secondary antibody (GE-Healthcare, UK).  
Blots were washed again and visualized by ECL system (GE-Healthcare, UK). The 
optical density of the bands was determined by Chemi Doc Imaging System (Bio-Rad). By 
incubating PVDF membrane in parallel with Tubulin antibody (1:5,000), normalization of 
results was obtained.  
 Specific antibodies were: mouse monoclonal anti-VEGF (1:200), rabbit polyclonal 
anti-eNOS (1:500), rabbit polyclonal anti-phosphorilated eNOS (Ser 1177) (1:250), mouse 
monoclonal anti nNOS (1:1000) and rabbit polyclonal anti iNOS (1:500). Antibodies were 
purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA. 
 
 
3.6 Quantification of GFP-cells 
To quantify the number of bone mesenchymal stem cells expressing the enhanced 
green fluorescent protein (GFP-BMSCs) injected after MCAO, we analyzed forty 
representative stop-frame images (20x objective) per animal. We calculated fluorescent 
cells located in the interstitium and into the vessels wall to clarify the distribution in the 
infarcted area. The distribution of these cells in the pial surface, was calculated as number 
of cells localized in the total infarcted area, considering the same uniform distribution for 
the entire thickness of the lesion.  
 
3.7 Neurological assessment 
All animals were subjected  to a battery of behavioural tests before MCAO and at 
different reperfusion time, using a modified neurological severity score, as previously 
described by Chen and coworkers [58].  
 
3.8 Statistical analysis  
All data were expressed as mean  SEM. Data were tested for normal distribution 
with the Kolmogorov-Smirnov test. Parametric (Student’s t tests, ANOVA and Bonferroni 
post hoc test) or nonparametric tests (Wilcoxon, Mann-Whitney and Kruskal-Wallis tests) 
were used; nonparametric tests were applied to compare diameter and length data among 
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experimental groups. The statistical analysis was carried out by SPSS 14.0 statistical 
package. Statistical significance was set at p<0.05. 
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4. RESULTS 
In sham-operated animals pial arteriolar networks showed the same geometric 
characteristics when observed in both parietal hemispheres. Pial arterioles, seldom 
organized in arcading vessels, were classified according to diameter, length and branching. 
Order 0 was assigned to the capillaries; subsequently, the terminal arterioles were assigned 
order 1 (mean diameter: 15.5  0.7 m) and the vessels upstream were assigned 
progressively higher orders (mean diameter: 23.0  0.5 m, 34.0  0.6 m and 44.5  0.7 
m for order 2, 3 and 4, respectively) (table 1).  
 
 
Order Arteriole 
N 
Diameter 
µm 
Lenght 
µm 
Rats 
5 10 63.0  0.4* 1.169  420 9 
4 27 44.5  0.7* 987  250 9 
3 78 34.0  0.6* 481  120 9 
2 113 23.0  0.5* 360  100 9 
1 109 15.5  0.7* 140  83 9 
 
             Table 1. Diameter and length of each arteriolar order in sham operated group. 
 
Data obtained from S group were pooled; the diameter (a), length (b) and branching 
distribution (c) in successive orders of arterioles obeyed Horton’s law, according to the 
following equations: 
(a) Log10Dn = a + bn 
(b) Log10Ln = a + bn 
(c) Log10Nn = a + bn 
where a and b are 2 constants. The logarithm of diameter, length and branching was 
directly proportional to vessel order number. Diameter, length and branching ratios, 
calculated from the slope of curves, were 1.39, 1.70 and 1.62, respectively. 
The branching vessels in the pial networks were described by connectivity matrix 
indicating vessel connection of one order to another. Usually an order 4 arteriole gave 
origin to most order 3 vessels (table 2a). 
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Blood brain barrier integrity was preserved in all sham-operated animals and 
leukocyte adhesion was not detected (table 3). PCD was 106.1 ± 2.3 cm
-1 
(table 3). All 
venular vessels were perfused (Fig. 3A, table 3). 
 
4.1 MCAO plus 1 hour of reperfusion 
Affected hemisphere presented an ischemic core devoid of blood flow, because all 
core vessels were not visualized by fluorescent dextran;  penumbra area was characterized 
by reduced blood flow (Fig. 3B). Pial microvasculature was markedly compromised; 
therefore, no vessel geometric evaluation was performed. Penumbra microvascular 
permeability was marked as well as leukocyte adhesion (table 3). PCD was reduced to 62.0 
 1.4 cm-1 (p<0.01 vs. S group).  
Few perfused large venules were detected in affected hemisphere penumbra 
compared with contralateral ones, where no changes in arteriolar, capillary and venular 
architecture and blood flow were observed. 
 
4.2 MCAO plus 7, 14 and 28 days of reperfusion 
After 7 and 14 days of reperfusion, arterioles gradually increased in number and 
length;  at 28 days of reperfusion, pial arteriolar networks regained diameter ratio as in 
sham-operated group, but length and branching ratios were higher and lower, respectively. 
Pial networks were characterized by arcading anastomotic arterioles overlapping the 
necrotic core. 
 These vessels appeared at 7 days of reperfusion and were progressively longer 
(Fig.3C); in C28R their number was the highest compared to all previous ischemic groups 
(Fig.3G). Order 2 and 1 anastomotic arterioles gave origin to order 2 and 1 vessels (table 
2d). 
Connectivity matrix indicates that order 4 arterioles were mainly connected to most 
order 2 vessels in C7R and C14R groups (table 2b, 2c). Order 4 arterioles gave origin to 
most order 3 vessels only in C28R group (table 2d). 
Microvascular permeability progressively decreased in C7R, C14R and C28R 
groups (table 3). The same time-dependent changes were observed for leukocyte adhesion, 
progressively decreasing according to increasing reperfusion time. Conversely, PCD 
gradually increased, up to 28 days of reperfusion (85.0 ± 1.2 cm-1, p< 0.01 vs. S group), 
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(table 3). Venular networks were characterized by progressive increase in number of 
perfused vessels from 7 days of reperfusion up to 14 days of reperfusion when the number 
of perfused vessels was in the same range as in contralateral pial microcirculation. At 28 
days of reperfusion venules were comparable in number with those observed in S group. 
The physiological parameters such as hematocrit, MABP, heart rate, pH, PCO2 and 
PO2 did not change in the different experimental groups. 
 
4.3 MCAO plus BMSCs after  7, 14 and 28 days of reperfusion 
BMSCs, injected after MCAO, were able to accelerate the remodeling processes. 
After 7 and 14 days of reperfusion, BMSCs stimulated a complex geometric pial networks 
compared with the respective groups of ischemic rats not treated with BMSCs (Fig. 3D, 
3F). Asymmetry was greater in larger vessels, as confirmed by the connectivity matrix 
showing that vessels of greater orders did not give rise to vessels of the order immediately 
lower, as reported in sham operated animals and in contralateral hemisphere (table 2e, 2f, 
2g). Interstitial edema quantified by the fluorescent dextran outside of vessels, at 7 and 14 
days is low when compared with the corresponding groups not treated with BMSCs (0.26 ± 
0.03 NGL vs 0.47 ± 0.02 C7R  e 0.18 ± 0.04 NGL vs 0.40 ± 0.03 C14R, respectively). 
The number of adherent leukocytes after 7 and 14 days was 4.0 ± 0.3 and 3.0 ± 0.4/ 
100 μm venular length/30s, respectively (p<0.01 vs baseline and C7R and C14R). The 
capillary density took on a value greater compared to untreated groups (78 ± 1.5 cm/cm
2
 vs 
67 ± 1.0 cm/cm
2
 CR7, 90 ± 1.2 cm/cm
2
 vs 70 ± 1.4  cm/cm
2 
C14R), (table 3). In 
BMSCs28R group, the animals showed recovered pial networks with anastomotic vessels 
overlapping the ischemic core (Fig. 3H).  
The characteristics of the different orders of vessels described by the connectivity 
matrix followed the same trend as observed in sham operated animals. The order 4 
originated mostly vessels of order 3 and 2, few of order 1 and no capillaries. Vessels of 
order 3 gave rise to most vessels of order 2, few of order 1 and no capillaries. The vessels of 
order 2 originated many vessels of order 1 and finally, the vessels of order 1 gave origin to 
most capillaries (Table 2g). 
 Indeed, microvascular permeability and leukocyte adhesion were decreased, 
capillary density was significantly increased more than in sham operated animals (table 3). 
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 The physiological parameters such as hematocrit, MABP, heart rate, pH, PCO2 and 
PO2 did not change in the different experimental groups. 
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Figure 3. Computer-assisted image of a rat pial microvascular network in sham operated animals 
(A), after two hours MCAO and 1 hour (C1hR group) (B), 7days (C7R group) (C), 14 days (C14R 
group) (E) and after 28 days of reperfusion (G). In treated group (D), after two hours MCAO plus 
BMSCs and 7 days (BMSCs7R group) (D), 14 days (BMSCs14R group) (F) and 28 days 
(BMSCs28R group) (H) of reperfusion. 
Scale bar = _____ 100 μm. 
 
 
 
 
 
        Order n                                             Order m 
            1                             2                             3                              4                            
0 2.28  0.40 
(89) 
0.23  0.15 
(7) 
0 0 
1 0.21  0.11 
(8) 
2.06  0.54 
(64) 
0.65  0.18 
(17) 
0.49  0.11 
(5) 
2 0 0.25  0.10 
(8) 
      1.79  1.00 
            (46) 
1.43  0.70 
(14) 
3 0 0 0.40  0.16 
(10) 
2.50  0.90 
(25) 
4 
 
0 
 
0 
 
0 
 
0.15  0.08 
(1) 
 
 
 
Order  N 
4 10 
3 26 
2 31 
1 39 
N: number of vessels studied  
for each order  
               Table 2a: connectivity matrix of pial arterioles in Sham operated group 
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Order n                                             Order m 
            1                             2                              3                             4                            
0 1.94  0.30 
(45) 
0.70  0.09 
(13) 
0 0 
1 0.38  0.14 
(9) 
0.89  0.13 
(16) 
1.27  0.25 
(25) 
0.31  0.11 
(2) 
2 0 0.62  0.17 
(11) 
      0.25  0.12 
              (5) 
1.55  0.42 
(11) 
3 0 0 0.36  0.13 
(7) 
0.20  0.08 
(1) 
4 
 
0 
 
0 
 
0 
 
0 
 
 
Order N 
4 7 
3 20 
2 18 
1 23 
 
N: Number of vessels studied for each order 
          
                Table 2b: connectivity matrix of pial arterioles in C7R group 
 
 
 
Order n                                             Order m 
            1                             2                              3                             4                            
0 2.43  0.32 
(73) 
1.12  0.11 
(21) 
0 0 
1 0.45  0.12 
(13) 
0.94  0.29 
(18) 
1.86  0.13 
(41) 
0.48  0.20 
(4) 
2 0 0.35  0.15 
(7) 
      0.54  0.12 
             (12) 
1.77  0.21 
(16) 
3 0 0 0.60  0.22 
(13) 
1.57  0.40 
(14) 
4 
 
0 
 
0 
 
0 
 
0 
 
 
Order N 
4 9 
3 22 
2 19 
1 30 
 
N: Number of vessels studied for each order 
 
                Table 2c: connectivity matrix of pial arterioles in C14R group 
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Order n                                             Order m 
             1                            2                              3                              4                            
0 2.22  0.38 
(69) 
0.25  0.12 
(4) 
0 0 
1 0.33  0.14 
(10) 
0.52  0.12 
(9) 
0.28  0.11 
(7) 
0 
2 0 0.28  0.15 
(5) 
      1.24  0.80 
             (30) 
0.66  0.23 
(7) 
3 0 0 0.29  0.10 
(7) 
1.33  0.46 
(15) 
4 
 
0 
 
0 
 
0 
 
0.33  0.10 
(4) 
 
 
Order N 
4 11 
3 24 
2 18 
1 31 
 
N: Number of vessels studied for each order 
 
              Table 2d: connectivity matrix of pial arterioles in C28R group 
 
 
Order n                                             Order m 
            1                             2                              3                              4                            
0 3.10  0.72 
(93) 
 
1.66  0.14 
(41) 
1.77  0.25 
(39) 
0 
1 0.90  0.19 
(27) 
 
2.00  0.18 
(50) 
2.97  0.15 
(65) 
 
0.88  0.56 
(7) 
 
2 0 0.85  0.15 
(21) 
 
      0.34  0.10 
(7) 
 
2.00  0.23 
(16) 
3 0 0 0.38  0.07 
(8) 
 
0.75  0.13 
(6) 
4 
 
0 
 
0 
 
0 
 
0 
 
 
 
Order N 
4 8 
3 22 
2 25 
1 30 
 
N: Number of vessels studied for each order 
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               Table 2e: connectivity matrix of pial arterioles in BMSCs7R group 
 
Order n                                             Order m 
            1                             2                              3                             4                            
0 4.35  0.32 
(152) 
 
1.60  0.78 
(43) 
0 0 
1 0.76  0.12 
(27) 
 
3.80  0.33 
(103) 
 
3.05  0.90 
(70) 
 
0.95  0.33 
(9) 
 
2 0 1.13  0.85 
(31) 
 
      4.52  0.24 
(104) 
 
2.10  0.34 
(19) 
 
3 0 0 0.50  0.18 
(12) 
 
1.98  0.26 
(18) 
 
4 
 
0 
 
0 
 
0 
 
0 
 
 
 
Order N 
4 9 
3 23 
2 27 
1 35 
 
N: Number of vessels studied for each order 
 
              Table 2f: connectivity matrix of pial arterioles in BMSCs14R group 
  
 
Order n                                             Order m 
            1                            2                                3                            4                            
0 5.15  0.18 
(216) 
 
4.20  0.55 
(126) 
 
0 0 
1 2.37  0.60 
(100) 
 
2.95  0.88 
(89) 
 
2.62  0.37 
(73) 
 
1.25  0.13 
(13) 
2 0 1.93  0.25 
(58) 
 
      1.50  0.95 
(42) 
 
4.70  0.25 
(47) 
 
3 0 0 1.76  0.43 
(49) 
 
1.57  0.30 
(16) 
 
4 
 
0 
 
0 
 
0 
 
0.21  0.08 
(2) 
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Order N 
4 10 
3 28 
2 30 
1 42 
N: Number of vessels studied for each order 
 
              Table 2g: connectivity matrix of pial arterioles in BMSCs28R group 
 
 
Group Microvascular 
permeability 
 
(NGL) 
Leukocyte 
Adhesion 
 
(Number of 
leukocytes/100 μm 
of venular 
length/30s) 
Capillary 
perfusion 
 
(cm-1) 
S 0.02 ± 0.01 1.0 ± 0.5 106.0 ± 2.3 
C1Hr 0.62 ± 0.03 ° 10.0 ± 0.5 ° 62.0 ± 1.4 ° 
C7R 0.47 ± 0.02 ° 8.0 ± 0.5 ° 67.0± 1.0 ° 
C14R 0.40 ± 0.03 ° 6.0 ± 0.5 ° 70.0 ± 1.4 ° 
C28R 0.20 ± 0.02° 3.0 ± 0.2 ° 85.1 ± 1.2 ° 
BMSCs7R 0.26 ± 0.03° 4.0 ± 0.3 ° 78 ± 1.5 ° 
BMSCs14R 0.18 ± 0.04° 3.0 ± 0.4 ° 90 ± 1.2 ° 
BMSCs28R 0.06 ± 0.03° 0.9 ± 0.8 ° 123 ± 1.8 ° 
 
Table 3. Summary of the principal parameters in sham-operated (S) group, in rats subjected to 2 
hours of MCAO and 1h, 7 days, or 14 days or 28 days of reperfusion (C1hR, C7R, C14R and C28R 
group, respectively) and in rats underwent to 2 hours of MCAO plus BMSCs and 7, 14, 28 days of 
reperfusion (BMSCs7R, BMSCs14R, BMSCs28R group, respectively). 
Capillary perfusion is expressed as cm
-1
. NGL: Normalized Grey Levels. Leukocyte adhesion, 
expressed as number of adherent leukocytes to 100 μm of venular length for 30 s.  
°p<0.01 vs. S group. 
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4.4 VEGF, eNOS, nNOS and iNOS  expression 
To assess the role played by VEGF and the three different NOS proteins present in 
the brain of treated rats, their expression was evaluated in the ipsilesional (IPSI) 
temporoparietal cortex and striatum of rats subjected to MCAO plus BMSCs at different 
reperfusion time intervals: 7, 14 and 28 days, and compared with the expression of the 
same proteins in not treated rats.  
We found that VEGF protein peaked on day 7 in the IPSI cortex and striatum, while 
on day 14 and 28 there was a decrease (Fig. 5). The same trend of the other proteins studied 
(e-NOS, p-eNOS, n-NOS and i-NOS) was detected (Fig 4, 6). 
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Figure 4:Western blotting of eNOS and phosphorilated eNOS expression in the cortex and striatum 
of sham-operated (CTX and STR), ischemic animals (CTX and STR) and of treated animals (TR 
CTX and TR STR); the corresponding densitometric values (mean ± SEM), expressed as arbitrary 
units calculated for each experimental group, were normalized on the basis of the respective ɑ-
tubulin. Each single experiment was repeated three times.* p<0.01 versus S and respective ischemic 
group in cortex. ° p<0.01 versus S and respective ischemic group in striatum.  
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Figure 5:Western blotting of i-NOS and VEGF expression in the cortex and striatum of sham-
operated (CTX and STR), ischemic animals (CTX and STR) and of treated animals (TR CTX and 
TR STR); the corresponding densitometric values (mean ± SEM), expressed as arbitrary units 
calculated for each experimental group, were normalized on the basis of the respective ɑ-tubulin. 
Each single experiment was repeated three times. .* p<0.01 versus S and respective ischemic group 
in cortex. ° p<0.012 versus S and respective ischemic group in striatum. 
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Figure 6:Western blotting of n-NOS expression in the cortex and striatum of sham-operated (CTX 
and STR), ischemic animals (CTX and STR) and of treated animals (TR CTX and TR STR); the 
corresponding densitometric values (mean ± SEM), expressed as arbitrary units calculated for each 
experimental group, were normalized on the basis of the respective ɑ-tubulin. Each single 
experiment was repeated three times. .* p<0.011 versus S and respective ischemic group in cortex. ° 
p<0.01 versus S and respective ischemic group in striatum. 
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4.5 GFP-BMSCs distribution in infarcted area 
At seven days from GFP-BMSCs injection, into the infarcted area, a lot of these 
cells were distributed at random (Fig. 7A). After fourteen days of reperfusion these cells 
increased in number and were organized to form straight lines, in parallel to viable vessels 
(Fig. 7B). In the last group treated with these cells, after twenty-eight days of reperfusion, a 
reduced number of cells was observed into the interstitium compared to the previous group.  
However it is worth noting, fluorescence was detected along the vessel walls (Fig. 7C). 
It was possible to observe, at higher magnification, the presence of GFP mesenchymal stem 
cells into the vessel walls (Fig. 7D). 
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Figure 7: Computer-assisted image of GFP-BMSCs in infarcted area of rat pial microvascular 
network after MCAO and 7 days (A), 14 days (B) and 28 days of reperfusion (C, D).  
Scale bar = _____ 100 μm. 
 
 
 
 
 
 
 
 
 
 
Table 4: Quantitative distribution of GFP-BMSCs in infarcted area after 7, 14 and 28 days of 
reperfusion. *p<0.01 vs GFP-BMSCs7R, °p<0.01 vs GFP-BMSCs14R. 
 
 
4.6 Neurological assessment 
No significant differences in the behavioural tests were detected among the 
experimental groups before MCAO; the score was 0 (normal). Increasing the reperfusion 
time all treated animals showed a progressive decrease in behavioural deficits compared to 
ischemic animals. BMSCs28R group recovered from neurological damage: the score was 
1.0 ± 0.5 (mild injury; p<0.01 vs. baseline conditions), (Fig. 8). 
 
0
50000
100000
150000
200000
250000
300000
*
*
 G
F
P
-B
M
S
C
s
 
7 days               14 days                28 days
 44 
0
2
4
6
8
 Ischemic groups
 Treated groups
N
e
u
ro
lo
g
ic
a
l 
S
e
v
e
ri
ty
 S
c
o
re
Baseline               R7days              R14 days           R28days
 
Figure 8: Neurological severity score of ischemic and treated animals 
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5. DISCUSSION AND CONCLUSIONS 
The results of the present study indicate the post-ischemic penumbra induced by 
MCAO is a site of intense microvascular reorganization, characterized by new vessel 
connections resulting in several anastomotic arterioles.  
MCAO for two hours and subsequent reperfusion for one hour caused an ischemic 
zone devoid of vessels, while the penumbra area presented few arterioles, capillaries, larger 
venules and marked microvascular permeability as well as marked leukocyte adhesion. 
These results are in accord with the observations by del Zoppo [59], because immediate 
events include breakdown of the primary endothelial cell barrier, plasma leakage and 
expression of endothelial cell leukocyte adhesion receptors.  
After 7 and 14 days of reperfusion, perfused arterioles progressively increased in 
number, showing a different geometric arrangement. Connectivity matrix indicates parent 
vessels were connected to smaller arterioles than in S group, characterized by order n+1 
arterioles giving origin to most order n arterioles. In ischemic animals until twenty-eight 
days of reperfusion parent vessels were not connected with (a majority of) daughter vessels 
of immediately successive order; therefore, an order gap was observed, i.e. predominant 
connections of the largest with the smallest arterioles. Moreover, vessel branchings in 
ischemic animals were not the same as in sham-operated group.  
It is reasonable to suggest that the increase in number of perfused arterioles at seven 
days of reperfusion give origin to new branchings with vessel formation and connections, as 
suggested by anastomotic arterioles appearing after seven days and increasing in number at 
fourteen days of reperfusion. These vessels constituted arteriolar arcades overlapping and 
supplying blood to ischemic core. Vascular remodeling was complex and involved vessel 
adjustment in length and branchings until twenty-eight days of reperfusion. 
The intracarotid administration of bone mesenchymal stem cells post middle 
cerebral artery occlusion induced an accelerated pial vascular remodeling.  
 We could compare the geometric reorganization of arteriolar networks in treated 
and not treated groups; moreover we compared treated group after 7 days of reperfusion 
with the ischemic group after 14 days of reperfusion. At 14 days of reperfusion we 
detected the same geometric characteristics observed after 28 days of reperfusion in not 
treated group. We could suggest that the role of these cells was to anticipate the 
remodeling processes of pial networks, because at 7 days of reperfusion in treated groups 
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we have the same microvascular arrangement as in not treated groups after 14 days. A 
pronounced number, indeed, of anastomotic arcading arterioles characterized the pial 
microvasculature. These arcades were likely vessels sprouting from preexistent arterioles 
localized in the penumbra area, able to overlap the ischemic core. Comparing the 
connectivity matrix obtained from the different experimental preparation, we noticed in the 
treated groups that arterioles of n+1 order give origin to most anastomotic vessel of order 
n. 
VEGF, the most important mitogen in the process of angiogenesis, promotes the 
vascular remodelling. We show that BMSCs increase the expression of this protein and 
induce the other protein expression playing an important role in the mechanism of 
remodelling. 
 eNOS and p-eNOS expression peaked after 7 days of reperfusion the expression. 
Conversely, the inducible NOS expression decreased; this effect induced by transplantation 
cells cause reduced expression of inflammatory factors helping to minimize post-ischemic 
inflammation and ischemic damage in the host brain [60].  
nNOS was induced and activated in penumbra and core during acute phase of 
experimental stroke [26]; the long-lasting production of NO might induce neurotoxic 
damage. Previous data indicated that the infarct volume after experimental stroke 
decreased significantly in nNOS gene knockout or nNOS inhibition [61, 62]. Our data, 
indeed, show that nNOS expression in cortex and striatum was reduced by treatment of 
BMSCs. Therefore, BMSCs can provide a resource of several trophic and growth factors, 
playing important roles in angiogenesis and stimulating differentiation of BMSCs [63].  
 GFP-BMSCs were useful to show the distribution and the organization of these 
cells into the infarcted area. More GFP-BMSCs were found in the lesioned hemisphere 
after 7 days. Distruption of the blood-brain barrier after MCAO may facilitate selective 
entry of BMSCs into ischemic brain compared with nonischemic contralateral hemisphere 
[58]. After fourteen days these cells were organized in penumbra area to form straight 
lines, suggesting a model for vessel tube formation. In the last group of treated animals 
with GFP-BMSCs, after 28 days  we observed marked fluorescence along the vessel walls 
and a reduced number of cells into the penumbra area. Therefore, the role of these cells 
into the vessels might be flowmotion of linear sprouting of new branching was 
fundamental to contribute to  remodeling processe acceleration. 
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This was accompanied by behavioural data from the battery of functional tests 
demonstrating that motor and sensory functions progressively recovered after ischemic 
insult. Significantly better performances were detected at 28 days of reperfusion after 
BMSCs injection. Therefore, neuronal recovery accompanied vascular remodelling.  
In conclusion, pial vascular remodeling after transient middle cerebral artery 
occlusion mainly involves arteriolar networks. The graft of bone mesenchymal stem cells 
accelerate these processes. An increasing  number of anastomotic arcading arterioles 
characterize pial microvasculature. These arcades were likely vessels sprouting from 
preexistent arterioles localized in the penumbra area, able to overlap the ischemic core. 
 Accelerate remodeling mechanisms appeared accompained by higher expression of 
VEGF and eNOS likely modulating  angiogenesis in vivo. Finally, cerebral microvessels 
remodeling was accompanied by improved neurological behaviour. 
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